DDInter1407 DDInter1956
Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients. Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) resulting in less use of Peginterferon alfa-2a. Peginterferon alfa-2a is derived from the alfa-2a moeity of recombinant human interferon and acts by binding to human type 1 interferon receptors. Activation and dimerization of this receptor induces the body's innate antiviral response by activating the janus kinase
A dideoxynucleoside compound in which the 3'-hydroxyl group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of 5' to 3' phosphodiester linkages, which are needed for the elongation of DNA chains, thus resulting in the termination of viral DNA growth. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.
Peginterferon alfa-2a {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Didanosine
Didanosine {u} (Compound) resembles {v} (Compound) Zalcitabine
Peginterferon alfa-2a {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cyclophosphamide
Cyclophosphamide {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Zalcitabine
Peginterferon alfa-2a {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Didanosine
Didanosine {u} (Compound) binds {v} (Gene) SLC22A6
SLC22A6 {u} (Gene) is bound by {v} (Compound) Zalcitabine
Peginterferon alfa-2a {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cyclophosphamide
Cyclophosphamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cytarabine
Cytarabine {u} (Compound) resembles {v} (Compound) Zalcitabine
Peginterferon alfa-2a {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Asparaginase Erwinia chrysanthemi
Asparaginase Erwinia chrysanthemi {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cytarabine
Cytarabine {u} (Compound) resembles {v} (Compound) Zalcitabine
Peginterferon alfa-2a {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Didanosine
Didanosine {u} (Compound) causes {v} (Side Effect) Decreased appetite
Decreased appetite {u} (Side Effect) is caused by {v} (Compound) Zalcitabine
Peginterferon alfa-2a {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Zafirlukast
Zafirlukast {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Didanosine
Didanosine {u} (Compound) resembles {v} (Compound) Zalcitabine
Peginterferon alfa-2a {u} may cause a minor interaction that can limit clinical effects when taken with {v} Methadone
Methadone {u} (Compound) causes {v} (Side Effect) Libido decreased
Libido decreased {u} (Side Effect) is caused by {v} (Compound) Zalcitabine
Peginterferon alfa-2a {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fluvastatin
Fluvastatin {u} (Compound) upregulates {v} (Gene) GPC1
GPC1 {u} (Gene) is upregulated by {v} (Compound) Zalcitabine
Peginterferon alfa-2a {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anagrelide
Anagrelide {u} (Compound) downregulates {v} (Gene) CDC20
CDC20 {u} (Gene) is downregulated by {v} (Compound) Zalcitabine
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Didanosine and Didanosine (Compound) resembles Zalcitabine (Compound)
Peginterferon alfa-2a may cause a minor interaction that can limit clinical effects when taken with Cyclophosphamide and Cyclophosphamide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Zalcitabine (Compound)
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Didanosine and Didanosine (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Zalcitabine (Compound)
Peginterferon alfa-2a may cause a minor interaction that can limit clinical effects when taken with Cyclophosphamide and Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Cytarabine and Cytarabine (Compound) resembles Zalcitabine (Compound)
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi and Asparaginase Erwinia chrysanthemi may cause a moderate interaction that could exacerbate diseases when taken with Cytarabine and Cytarabine (Compound) resembles Zalcitabine (Compound)
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Didanosine and Didanosine (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Zalcitabine (Compound)
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast and Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Didanosine and Didanosine (Compound) resembles Zalcitabine (Compound)
Peginterferon alfa-2a may cause a minor interaction that can limit clinical effects when taken with Methadone and Methadone (Compound) causes Libido decreased (Side Effect) and Libido decreased (Side Effect) is caused by Zalcitabine (Compound)
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin (Compound) upregulates GPC1 (Gene) and GPC1 (Gene) is upregulated by Zalcitabine (Compound)
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Anagrelide and Anagrelide (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Zalcitabine (Compound)